KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Profit After Tax: 2011-2024

Historic Profit After Tax for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$321.5 million.

  • Travere Therapeutics' Profit After Tax rose 146.90% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.81%. This contributed to the annual value of -$321.5 million for FY2024, which is 14.56% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Profit After Tax is -$321.5 million, which was up 14.56% from -$376.3 million recorded in FY2023.
  • Over the past 5 years, Travere Therapeutics' Profit After Tax peaked at -$169.4 million during FY2020, and registered a low of -$376.3 million during FY2023.
  • Over the past 3 years, Travere Therapeutics' median Profit After Tax value was -$331.5 million (recorded in 2022), while the average stood at -$343.1 million.
  • In the last 5 years, Travere Therapeutics' Profit After Tax tumbled by 52.54% in 2022 and then grew by 14.56% in 2024.
  • Over the past 5 years, Travere Therapeutics' Profit After Tax (Yearly) stood at -$169.4 million in 2020, then fell by 28.25% to -$217.3 million in 2021, then slumped by 52.54% to -$331.5 million in 2022, then fell by 13.54% to -$376.3 million in 2023, then rose by 14.56% to -$321.5 million in 2024.